Patents Assigned to OCUNEXUS THERAPEUTICS, INC.
  • Channel modulators
    Patent number: 11401516
    Abstract: The inventions relate to compositions and articles of manufacture comprising connexin modulators, pannexin modulators, gap junction modulators, hemichannel modulators, and pannexin channel modulators and their use, alone or in combination, in treating ocular and other disorders.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: August 2, 2022
    Assignees: AUCKLAND UNISERVICES LIMITED, OCUNEXUS THERAPEUTICS, INC.
    Inventors: Colin Richard Green, Yeri Kim, Anthony Phillips, Bradford James Duft
  • Anti-connexin compounds targeted to connexins and methods of use thereof
    Patent number: 11390870
    Abstract: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use in post-surgical, trauma, or tissue engineering applications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication is desirable.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: July 19, 2022
    Assignee: OCUNEXUS THERAPEUTICS, INC.
    Inventors: Wilda Laux, Colin Richard Green
  • Cytokine modulation
    Patent number: 11344603
    Abstract: The inventions relate to the use of hemichannel blockers to modulate cytokine levels in a subject, including the angiogenic cytokine, VEGF, and their production, secretion and/or release, and to the use of hemichannel blockers to reduce or level cytokine activity, including in conditions characterized in whole or in part by angiogenesis and/or vessel leak.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: May 31, 2022
    Assignees: AUCKLAND UNISERVICES LIMITED, OCUNEXUS THERAPEUTICS, INC.
    Inventors: Colin Richard Green, Odunayo Omolola Boluwarin Mugisho, Bradford James Duft
  • Anti-connexin compounds targeted to connexins and methods of use thereof
    Patent number: 10787667
    Abstract: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use in post-surgical, trauma, or tissue engineering applications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication is desirable.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: September 29, 2020
    Assignee: OCUNEXUS THERAPEUTICS, INC.
    Inventors: Wilda Laux, Colin Richard Green
  • Anti-connexin compounds targeted to connexins and methods of use thereof
    Patent number: 10472632
    Abstract: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use in post-surgical, trauma, or tissue engineering applications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication is desirable.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: November 12, 2019
    Assignee: OCUNEXUS THERAPEUTICS, INC.
    Inventors: Wilda Laux, Colin Richard Green
  • Channel modulators
    Patent number: 10465188
    Abstract: The inventions relate to compositions and articles of manufacture comprising connexin modulators, pannexin modulators, gap junction modulators, hemichannel modulators, and pannexin channel modulators and their use, alone or in combination, in treating ocular and other disorders.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: November 5, 2019
    Assignees: AUCKLAND UNISERVICES LIMITED, OCUNEXUS THERAPEUTICS, INC
    Inventors: Colin Richard Green, Yeri Kim, Anthony Phillips, Bradford James Duft
  • Methods and compositions for wound healing
    Patent number: 10406174
    Abstract: Methods and compositions comprising combinations of one or more anti-connexin agents and one or more other agents useful for the promotion and/or improvement of wound healing and/or tissue repair.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: September 10, 2019
    Assignee: OCUNEXUS THERAPEUTICS, INC.
    Inventors: Colin R. Green, Bradford J. Duft, David L. Becker
  • Treatment of ocular disorders with anti-connexin proteins and mimetics
    Patent number: 10201590
    Abstract: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use for treatment of cardiovascular, vascular, neurological, for wounds and for other indications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication or prevention of hemichannel opening is desirable.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: February 12, 2019
    Assignee: OCUNEXUS THERAPEUTICS, INC.
    Inventors: Colin Richard Green, David Lawrence Becker
  • Anti-connexin compounds targeted to connexins and methods of use thereof
    Patent number: 10174316
    Abstract: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use in post-surgical, trauma, or tissue engineering applications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication is desirable.
    Type: Grant
    Filed: August 25, 2014
    Date of Patent: January 8, 2019
    Assignee: OCUNEXUS THERAPEUTICS, INC.
    Inventors: Wilda Laux, Colin Richard Green